Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 14, No. suppl_2, 30-40, October 2009; doi:10.1634/theoncologist.2009-S2-30
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Delbeke, D.
Right arrow Articles by Conti, P. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delbeke, D.
Right arrow Articles by Conti, P. S.

Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma

Dominique Delbekea, Sigrid Stroobantsb, Eric de Kervilerc, Christian Gisselbrechtc, Michel Meignand, Peter S. Contie

aVanderbilt University Medical Center, Nashville, Tennessee, USA; bUniversity Hospital, Gasthuisberg, Leuven, Belgium; cHôpital Saint-Louis, Paris, France; dHôpital Henri Mondor, Creteil, France; eUniversity of Southern California, Los Angeles, California, USA

Key Words. Positron emission tomography • Emission-computed tomography • Non-Hodgkin's lymphoma • Imaging

Correspondence: Peter S. Conti, M.D., Ph.D., Department of Radiology, University of Southern California, 1510 San Pablo Street, Room #350, Los Angeles, California 90033, USA. Telephone: 323-442-5940; Fax: 323-442-5778; e-mail: pconti{at}usc.edu

Received March 27, 2009; accepted for publication July 14, 2009.

Disclosures: Dominique Delbeke: Honoraria: GE Healthcare; Sigrid Stroobants: None; Eric de Kerviler: None; Christian Gisselbrecht: Research funding/contracted research: Bayer Schering Pharma; Michel Meignan: None: Peter S. Conti: Honoraria: Bayer Schering.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Revised guidelines for the staging and response criteria of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) were recently published to include the expanding role of positron emission tomography/computed tomography (PET/CT) using 18F-fluoro-2-deoxyglucose. Here, we discuss the new guidelines and the need for standardized PET acquisition and interpretation in HL and NHL. We also discuss how the role for CT is evolving in the process of making treatment decisions and provide insight on how best to standardize the use of PET/CT for making therapeutic choices.




This article has been cited by other articles:


Home page
 The OncologistHome page
A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory
Introduction
Oncologist, October 1, 2009; 14(suppl_2): 1 - 3.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.
Advertisement